No abuse potential shown in preclinical studies
We are delighted to share promising preclinical results for our innovative drug candidate PN6047, further confirming its safety profile. PN6047 is designed to provide relief from neuropathic pain, and these findings reinforce our commitment to safe and effective pain management as we prepare for Phase II trials in 2024.
Key outcomes from the preclinical studies:
- No abuse potential: PN6047 displayed no signs of abuse potential in animal models, marking a notable departure from conventional opioids.
- Alleviates the opioid withdrawal syndrome: PN6047 mitigated symptoms associated with opioid withdrawal in animal models.
These studies, conducted in collaboration with Washington University and the University of Michigan and supported by the US National Institute of Drug Abuse, represent a significant step forward in our mission to provide safe and effective pain relief without the risk of addiction or severe side effects. As we gear up for Phase II clinical trials in 2024, our commitment to redefining pain management remains unwavering.
No abuse potential shown in preclinical studies
We are delighted to share promising preclinical results for our innovative drug candidate PN6047, further confirming its safety profile. PN6047 is designed to provide relief from neuropathic pain, and these findings reinforce our commitment to safe and effective pain management as we prepare for Phase II trials in 2024.
Key outcomes from the preclinical studies:
- No abuse potential: PN6047 displayed no signs of abuse potential in animal models, marking a notable departure from conventional opioids.
- Alleviates the opioid withdrawal syndrome: PN6047 mitigated symptoms associated with opioid withdrawal in animal models.
These studies, conducted in collaboration with Washington University and the University of Michigan and supported by the US National Institute of Drug Abuse, represent a significant step forward in our mission to provide safe and effective pain relief without the risk of addiction or severe side effects. As we gear up for Phase II clinical trials in 2024, our commitment to redefining pain management remains unwavering.
Latest news
View all
Watch PharmNovo at LSX in Lisbon
Take the opportunity to listen to Per von Mentzer, CEO, presenting PN6047 at the LSX World Europe congress in Lisbon, March 2026. Learn how PharmNovo is shaping a new approach to pain relief with the goal to prove that powerful pain treatment doesn’t have to come with the cost of addiction. Discover how the company’s lead candidate PN6047, delivers effective pain relief without activating the mu-opioid receptor and avoiding the addiction risks associated with conventional opioids. The Phase II-ready Delta Opioid Receptor Agonist (DORA) with first-in-class potential, PN6047 represents a safer, non-addictive approach targeting a neuropathic pain market that is expected to double until 2033 and reach 13 bEUR.
Read more
Capsules ready for Phase IIa Study
PharmNovo is pleased to announce that that the company has completed drug product manufacturing for its lead candidate PN6047. This is an important milestone as the company prepares for its upcoming Phase IIa proof-of-concept study in neuropathic pain.
Read more
Welcome on Board
As the company prepares for the next phase of clinical development, the new Board composition strengthens our strategic capabilities ahead of Phase II development of our lead candidate, PN6047.
Read more
